Company news

Ascendis Pharma A/S news in 2024

Ascendis Pharma A/S's news releases, calls and decks from 2024, newest first.

View company

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

December 18, 2024

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

December 11, 2024

Calls in 2024

Decks in 2024